FBXW7 Regulates the Sensitivity of Imatinib in Gastrointestinal Stromal Tumors by Targeting MCL1

Overview

Journal Gastric Cancer

Specialties Gastroenterology
Oncology

Date 2023 Dec 24

PMID 38142463

Authors

Xiyu Wu

Masaaki Iwatsuki

Masakazu Takaki

Takuro Saito

Tsutomu Hayashi

Masato Kondo

Yoshiharu Sakai

Naoto Gotohda

Eiji Tanaka

Toshirou Nishida

Hideo Baba

Affiliations

Soon will be listed here.

Abstract

Background: Imatinib contributes to improving prognosis of high-risk or unresectable gastrointestinal stromal tumors (GISTs). As therapeutic efficacy is limited by imatinib resistance and toxicity, the exploration of predictive markers of imatinib therapeutic efficacy that enables patients to utilize more effective therapeutic strategies remains urgent.

Methods: The correlation between FBXW7 and imatinib resistance via FBXW7-MCL1 axis was evaluated in vitro and in vivo experiments. The significance of FBXW7 as a predictor of imatinib treatment efficacy was examined in 140 high-risk patients with GISTs.

Results: The ability of FBXW7 to predict therapeutic efficacy of adjuvant imatinib in high-risk GIST patients was determined through 5-year recurrence-free survival (RFS) rates analysis and multivariate analysis. FBXW7 affects imatinib sensitivity by regulating apoptosis in GIST-T1 cells. FBXW7 targets MCL1 to regulate apoptosis. MCL1 involves in the regulation of imatinib sensitivity through inhibiting apoptosis in GIST-T1 cells. FBXW7 regulates imatinib sensitivity by down-regulating MCL1 to enhance imatinib-induced apoptosis in vitro. FBXW7 regulates imatinib sensitivity of GIST cells by targeting MCL1 to predict efficacy of imatinib treatment in vivo.

Conclusions: FBXW7 regulates imatinib sensitivity by inhibiting MCL1 to enhance imatinib-induced apoptosis in GIST, and predicts efficacy of imatinib treatment in high-risk GIST patients treated with imatinib.

Citing Articles

STYX Interacts with FBXW7 to Promote AML Proliferation via Inhibiting the Ubiquitination of CCNE1.

Yang R, Ning J, Wang H, Ma H, Cui L Cell Biochem Biophys. 2025; .

PMID: 39962032 DOI: 10.1007/s12013-025-01692-8.

Elevated expression drives esophageal squamous cell carcinoma stemness and induces resistance to radiotherapy.

Chen J, Chen G, Fang X, Sun J, Song J, Chen Z J Thorac Dis. 2025; 16(12):8684-8698.

PMID: 39831242 PMC: 11740075. DOI: 10.21037/jtd-2024-2027.

FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects.

Wang W, Liu X, Zhao L, Jiang K, Yu Z, Yang R Front Pharmacol. 2025; 15:1505027.

PMID: 39749199 PMC: 11694028. DOI: 10.3389/fphar.2024.1505027.

YAP acts as an independent prognostic marker and regulates growth and metastasis of gastrointestinal stromal tumors via FBXW7-YAP pathway.

Wu X, Yamashita K, Matsumoto C, Zhang W, Ding M, Harada K J Gastroenterol. 2024; 60(3):275-284.

PMID: 39557657 DOI: 10.1007/s00535-024-02180-1.

References

Soreide K, Sandvik O, Soreide J, Giljaca V, Jureckova A, Bulusu V . Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2015; 40:39-46. DOI: 10.1016/j.canep.2015.10.031. View

Serrano C, George S . Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade. Clin Cancer Res. 2020; 26(19):5078-5085. DOI: 10.1158/1078-0432.CCR-20-1706. View

Casali P, Blay J, Abecassis N, Bajpai J, Bauer S, Biagini R . Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 33(1):20-33. DOI: 10.1016/j.annonc.2021.09.005. View

DeMatteo R, Lewis J, Leung D, Mudan S, Woodruff J, Brennan M . Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231(1):51-8. PMC: 1420965. DOI: 10.1097/00000658-200001000-00008. View

Patrikidou A, Chabaud S, Ray-Coquard I, Bui B, Adenis A, Rios M . Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol. 2012; 24(4):1087-93. DOI: 10.1093/annonc/mds587. View

Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R . Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005; 6(4):249-51. DOI: 10.1016/S1470-2045(05)70097-8. View

Alkhuziem M, Burgoyne A, Fanta P, Tang C, Sicklick J . The Call of "The Wild"-Type GIST: It's Time for Domestication. J Natl Compr Canc Netw. 2017; 15(5):551-554. PMC: 5549855. DOI: 10.6004/jnccn.2017.0057. View

Corless C, Barnett C, Heinrich M . Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011; 11(12):865-78. DOI: 10.1038/nrc3143. View

Burgoyne A, Somaiah N, Sicklick J . Gastrointestinal stromal tumors in the setting of multiple tumor syndromes. Curr Opin Oncol. 2014; 26(4):408-14. DOI: 10.1097/CCO.0000000000000089. View

10.

Bannon A, Klug L, Corless C, Heinrich M . Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. Expert Rev Mol Diagn. 2017; 17(5):445-457. DOI: 10.1080/14737159.2017.1308826. View

11.

Koepp D, Schaefer L, Ye X, Keyomarsi K, Chu C, Harper J . Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001; 294(5540):173-7. DOI: 10.1126/science.1065203. View

12.

Welcker M, Singer J, Loeb K, Grim J, Bloecher A, Gurien-West M . Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell. 2003; 12(2):381-92. DOI: 10.1016/s1097-2765(03)00287-9. View

13.

Nakayama K, Nakayama K . Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006; 6(5):369-81. DOI: 10.1038/nrc1881. View

14.

Koga Y, Iwatsuki M, Yamashita K, Kiyozumi Y, Kurashige J, Masuda T . The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer. 2019; 22(6):1100-1108. DOI: 10.1007/s10120-019-00950-y. View

15.

Mao J, Kim I, Wu D, Climent J, Kang H, Delrosario R . FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008; 321(5895):1499-502. PMC: 2849753. DOI: 10.1126/science.1162981. View

16.

Tong J, Wang P, Tan S, Chen D, Nikolovska-Coleska Z, Zou F . Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. Cancer Res. 2017; 77(9):2512-2521. PMC: 5626525. DOI: 10.1158/0008-5472.CAN-16-3242. View

17.

Zhong Q, Gao W, Du F, Wang X . Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell. 2005; 121(7):1085-95. DOI: 10.1016/j.cell.2005.06.009. View

18.

Ding Q, He X, Hsu J, Xia W, Chen C, Li L . Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol. 2007; 27(11):4006-17. PMC: 1900029. DOI: 10.1128/MCB.00620-06. View

19.

Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser R . SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011; 471(7336):104-9. PMC: 3076007. DOI: 10.1038/nature09732. View

20.

Wertz I, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson D . Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011; 471(7336):110-4. DOI: 10.1038/nature09779. View